ABSTRACT
AV7909 is a next-generation anthrax vaccine under development for post-exposure prophylaxis following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with the recommended antibacterial regimen. AV7909 consists of the FDA-approved BioThrax® vaccine (anthrax vaccine adsorbed) and an immunostimulatory Toll-like receptor 9 agonist oligodeoxynucleotide adjuvant, CPG 7909. The purpose of this study was to evaluate the potential systemic and local toxicity of AV7909 when administered via repeat intramuscular injection to the right thigh muscle (biceps femoris) to male and female Sprague Dawley rats. The vaccine was administered on Days 1, 15, and 29 and the animals were assessed for treatment-related effects followed by a 2-week recovery period to evaluate the persistence or reversibility of any toxic effects. The AV7909 vaccine produced no apparent systemic toxicity based on evaluation of clinical observations, body weights, body temperature, clinical pathology, and anatomic pathology. Necrosis and inflammation were observed at the injection sites as well as in regional lymph nodes and adjacent tissues and were consistent with immune stimulation. Antibodies against B. anthracis protective antigen (PA) were detected in rats treated with the AV7909 vaccine, confirming relevance of this animal model for the assessment of systemic toxicity of AV7909. In contrast, sera of rats that received saline or soluble CPG 7909 alone were negative for anti-PA antibodies. Overall, 3 intramuscular immunizations of Sprague Dawley rats with AV7909 were well tolerated, did not induce mortality or any systemic adverse effects, and did not result in any delayed toxicity.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Anthrax Vaccines/administration & dosage , Oligodeoxyribonucleotides/administration & dosage , Adjuvants, Immunologic/toxicity , Animals , Anthrax Vaccines/toxicity , Antibodies, Bacterial/blood , Antibodies, Neutralizing/blood , Antigens, Bacterial/immunology , Bacterial Toxins/immunology , Female , Injection Site Reaction/blood , Injection Site Reaction/etiology , Injection Site Reaction/immunology , Injection Site Reaction/pathology , Injections, Intramuscular , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/pathology , Oligodeoxyribonucleotides/toxicity , Post-Exposure Prophylaxis , Rats, Sprague-DawleyABSTRACT
Nonhuman primates (NHPs) and rabbits are the animal models most commonly used to evaluate the efficacy of medical countermeasures against anthrax in support of licensure under the FDA's "Animal Rule." However, a need for an alternative animal model may arise in certain cases. The development of such an alternative model requires a thorough understanding of the course and manifestation of experimental anthrax disease induced under controlled conditions in the proposed animal species. The guinea pig, which has been used extensively for anthrax pathogenesis studies and anthrax vaccine potency testing, is a good candidate for such an alternative model. This study was aimed at determining the median lethal dose (LD50) of the Bacillus anthracis Ames strain in guinea pigs and investigating the natural history, pathophysiology, and pathology of inhalational anthrax in this animal model following nose-only aerosol exposure. The inhaled LD50 of aerosolized Ames strain spores in guinea pigs was determined to be 5.0 × 10(4) spores. Aerosol challenge of guinea pigs resulted in inhalational anthrax with death occurring between 46 and 71 h postchallenge. The first clinical signs appeared as early as 36 h postchallenge. Cardiovascular function declined starting at 20 h postexposure. Hematogenous dissemination of bacteria was observed microscopically in multiple organs and tissues as early as 24 h postchallenge. Other histopathologic findings typical of disseminated anthrax included suppurative (heterophilic) inflammation, edema, fibrin, necrosis, and/or hemorrhage in the spleen, lungs, and regional lymph nodes and lymphocyte depletion and/or lymphocytolysis in the spleen and lymph nodes. This study demonstrated that the course of inhalational anthrax disease and the resulting pathology in guinea pigs are similar to those seen in rabbits and NHPs, as well as in humans.
Subject(s)
Anthrax/pathology , Anthrax/physiopathology , Bacillus anthracis/pathogenicity , Disease Models, Animal , Animals , Anthrax/mortality , Female , Guinea Pigs , Lethal Dose 50 , Male , Survival Analysis , Time FactorsABSTRACT
The Mn0.720Ni0.175Co0.105(OH)2 precursor was co-precipitated by the Couette-Taylor reactor. The 0.3Li2MnO3 x 0.7LiMn0.60Ni0.25Co0.15O2 of the high capacity cathode material for a Li-ion battery was synthesized according to the amount of lithium excess (5-20 mol.%). X-ray diffraction (XRD) and field emission-scanning electron microscopy (FE-SEM) were used to characterize the 0.3Li2MnO3 x 0.7Li-Mn0.60Ni0.25Co0.15O2. Based on the XRD patterns and FE-SEM images, the 5 and 10 mol.% lithium excess samples were observed for spinel structure. The 15 and 20 mol.% lithium excess samples were not observed for the structure. We can conclude that the spinel structure was made in 0.3Li2MnO3 x 0.7LiMn0.60-Ni0.25Co0.15O2, due to a lack of lithium. The discharge specific capacity of 5, 10, 15, and 20 mol.% lithium excess were measured at 216, 246, 262, and 261 mA h g(-1), respectively. Cyclic voltammograms show that the Li2MnO3 has a lower lithium influence than a spinel or layered structure. Based on these experiment results, we can conclude that the best Li source amount of the 0.3Li2MnO3 x 0.7LiMn0.60-Ni0.25Co0.15O2 synthesis is a 15 mol.% excess.
Subject(s)
Electric Power Supplies , Electrodes , Lithium/chemistry , Metal Nanoparticles/chemistry , Metal Nanoparticles/ultrastructure , Crystallization/methods , Electric Conductivity , Equipment Design , Equipment Failure Analysis , Ions , Macromolecular Substances/chemistry , Materials Testing , Molecular Conformation , Particle Size , Surface PropertiesABSTRACT
A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasures in humans are not ethical or feasible, therefore, licensure of AV7909 for PEP is being pursued under the US Food and Drug Administration (FDA) Animal Rule, which requires that evidence of effectiveness be demonstrated in an animal model of anthrax, where results of studies in such a model can establish reasonable likelihood of AV7909 to produce clinical benefit in humans. Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens. Three times per day (TID) intraperitoneal (IP) dosing with 7.5 mg/kg of ciprofloxacin initiated 1 day following inhalational anthrax challenge and continued for 14 days was identified as a well tolerated partially curative ciprofloxacin treatment regimen. The added benefit of AV7909 vaccination was evaluated in guinea pigs given the partially curative ciprofloxacin treatment regimen. Groups of ciprofloxacin-treated guinea pigs were vaccinated. 1 and 8 days post-challenge with serial dilutions of AV7909, a 1:16 dilution of AVA, or normal saline. A group of untreated guinea pigs was included as a positive control to confirm lethal B. anthracis exposure. Post-exposure vaccination with the AV7909 anthrax vaccine candidate administered in combination with the partially curative ciprofloxacin treatment significantly increased survival of guinea pigs compared to ciprofloxacin treatment alone. These results suggest that the developed model can be useful in demonstrating added value of the vaccine for PEP.
Subject(s)
Anthrax Vaccines/administration & dosage , Anthrax , Disease Models, Animal , Post-Exposure Prophylaxis , Respiratory Tract Infections , Animals , Anthrax/prevention & control , Anti-Bacterial Agents/pharmacokinetics , Ciprofloxacin/pharmacokinetics , Guinea Pigs , Respiratory Tract Infections/prevention & controlABSTRACT
No vaccine exists for the prevention of infection with the ubiquitous gastric pathogen Helicobacter pylori, and drug therapy for the infection is complicated by poor patient compliance, the high cost of treatment, and ineffectiveness against drug-resistant strains. A new medical advancement is required to reduce the incidence of peptic ulcer disease and stomach cancer, two conditions caused by infection with H. pylori. Clinical trials have been performed with a formalin-inactivated H. pylori whole cell (HWC) vaccine, given orally in combination with the mucosal adjuvant mLT(R192G), a mutant of Escherichia coli heat-labile toxin. Following the initial dose of this vaccine, some subjects experienced gastrointestinal side effects. To reduce side effects and potentially further increase the amount of adjuvant that can safely be administered with the HWC vaccine, experiments were performed with a form of LT that carried two mutations in the A subunit, a substitution of G for R at position 192, and A for L at position 211. The double mutant LT (dmLT) adjuvant stimulated immune responses as effectively as the single mutant LT in mice. Additionally, following a challenge infection, the dmLT-adjuvanted vaccine was as effective as single mutant LT in reducing gastric urease levels (diagnostic for H. pylori infection), and H. pylori colonization in the stomach as assessed by quantitative analysis of stomach homogenates. A lyophilized formulation of HWC was developed to improve stability and to potentially reduce reliance on cold chain maintenance. It was observed that a dmLT-adjuvanted lyophilized vaccine was equally as protective in the mouse model as the liquid formulation as assessed by gastric urease analysis and analysis of stomach homogenates for viable H. pylori. No readily detectable effect of tonicity or moisture content was observed for the lyophilized vaccine within the formulation limits evaluated. In an accelerated stability study performed at 37 degrees C the lyophilized vaccine remained equally as protective as vaccine stored at 2-8 degrees C. The formulation selected for clinical development consisted of 2.5 x 10(10) formalin-inactivated cells per ml in 6.5% trehalose, 0.5% mannitol, and 10mM citrate buffer at pH 6.8.